Roseline D Oiron

Roseline D Oiron

Auto-generated profile, based on publicly available information

Roseline D Oiron

Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Rares, Hôpital Bicêtre APHP, and HITh, UMR_S1176, INSERM Université Paris‐Saclay, Le Kremlin‐Bicêtre Paris France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2004 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MPM‐C. Poon
M‐C. Poon
RDR. D'Oiron
R. D'Oiron
MDM. Von Depka
M. Von Depka
KKK. Khair
K. Khair
CNC. Négrier
C. Négrier
FGFOR MEMBERS OF THE INTERNATIONAL DATA COLLECTION ON RECOMBINANT FACTOR VIIa AND CONGENITAL PLATELET DISORDERS STUDY GROUP
FOR MEMBERS OF THE INTERNATIONAL DATA COLLECTION ON RECOMBINANT FACTOR VIIa AND CONGENITAL PLATELET DISORDERS STUDY GROUP

27 November 2014 in Blood
Verified
Journal Article
Open access
PDF file
TCThierry Calvez
Thierry Calvez
HCHervé Chambost
Hervé Chambost
SCSégolène Claeyssens-Donadel
Ségolène Claeyssens-Donadel
RDRoseline D’oIron
Roseline D’oIron
VGVéronique Goulet
Véronique Goulet
JGJenny Goudemand
Jenny Goudemand
Key Points: A currently marketed rFVIII product is associated with a higher risk of inhibitor development in boys with severe hemophilia A. This result, validated by extensive sensitivity analyses, confirms a recently published study and cannot be explained by identified biases.

1 April 2016 in Transfusion Medicine Reviews
Verified
Journal Article
Open access
MPMan-Chiu Poon
Man-Chiu Poon
GMGiovanni Di Minno
Giovanni Di Minno
RDRoseline D’oiron
Roseline D’oiron
RZRainer Zotz
Rainer Zotz
Glanzmann thrombasthenia (GT) is a rare inherited autosomal recessive bleeding disorder of platelet function caused by a quantitative or qualitative defect of platelet membrane glycoprotein IIb/IIIa (integrin αIIbβ3), a fibrinogen receptor required for platelet aggregation. Bleeds in GT are variable and may be severe and unpredictable. Bleeding not responsive to local and adjunctive measures, as well as surgical procedures, is treated with platelets, recombinant activated factor VII (rFVIIa), or antifibrinolytics, alone or in combination. Although platelets are the standard treatment for GT, their use is associated with the risk of blood-borne infection transmission and may also cause the development of platelet antibodies (to human leukocyte antigens and/or αIIbβ3), potentially resulting in platelet refractoriness. Currently, where rFVIIa is approved for use in GT, this is mostly for patients with platelet antibodies and/or a history of platelet refractoriness. However, data from the prospective Glanzmann's Thrombasthenia Registry (829 bleeds and 206 procedures in 218 GT patients) show that rFVIIa was frequently used in nonsurgical and surgical bleeds, with high efficacy rates, irrespective of platelet antibodies/refractoriness status. The mechanisms underpinning rFVIIa effectiveness in GT have been studied. At therapeutic concentrations, rFVIIa binds to activated platelets and directly activates FX to FXa, resulting in a burst of thrombin generation. Thrombin converts fibrinogen to fibrin and also enhances GT platelet adhesion and aggregation mediated by the newly converted (polymeric) fibrin, leading to primary hemostasis at the wound site. In addition, thrombin improves the final clot structure and activates thrombin-activatable fibrinolysis inhibitor to decrease clot lysis.

28 February 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SLSébastien Lacroix-Desmazes
Sébastien Lacroix-Desmazes
Jagadeesh BAYRYJagadeesh BAYRY
Jagadeesh BAYRY
NMNamita Misra
Namita Misra
MHMichael P. Horn
Michael P. Horn
SVSylvie Villard
Sylvie Villard
SKSrini V. Kaveri
Srini V. Kaveri
Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII.

25 February 2015 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ANAlan T. Nurden
Alan T. Nurden
XPXavier Pillois
Xavier Pillois
MFMathieu Fiore
Mathieu Fiore
MAMarie-Christine Alessi
Marie-Christine Alessi
MBMariana Bonduel
Mariana Bonduel
CVChristine Vinciguerra
Christine Vinciguerra
We report the largest international study on Glanzmann thrombasthenia (GT), an inherited bleeding disorder where defects of the ITGA2B and ITGB3 genes cause quantitative or qualitative defects of the αIIbβ3 integrin, a key mediator of platelet aggregation. Sequencing of the coding regions and splice sites of both genes in members of 76 affected families identified 78 genetic variants (55 novel) suspected to cause GT. Four large deletions or duplications were found by quantitative real‐time PCR. Families with mutations in either gene were indistinguishable in terms of bleeding severity that varied even among siblings. Families were grouped into type I and the rarer type II or variant forms with residual αIIbβ3 expression. Variant forms helped identify genes encoding proteins mediating integrin activation. Splicing defects and stop codons were common for both ITGA2B and ITGB3 and essentially led to a reduced or absent αIIbβ3 expression; included was a heterozygous c.1440‐13_c.1440‐1del in intron 14 of ITGA2B causing exon skipping in seven unrelated families. Molecular modeling revealed how many missense mutations induced subtle changes in αIIb and β3 domain structure across both subunits, thereby interfering with integrin maturation and/or function. Our study extends knowledge of GT and the pathophysiology of an integrin.

3 August 2021 in Haemophilia
Verified
Journal Article
Open access
PDF file
KGKarin van Galen
Karin van Galen
MLMichelle Lavin
Michelle Lavin
NSNaja Skouw‐Rasmussen
Naja Skouw‐Rasmussen
KFKathelijn Fischer
Kathelijn Fischer
DNDeclan Noone
Declan Noone
T(the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)
the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)
Introduction: Despite increasing awareness of issues faced by women and girls with inherited BDs (WGBD), standards of care are lacking, with disparities in diagnosis and treatment for WGBD across Europe. We aimed to develop practical principles of care (PoC) to promote standardization of care for WGBD within European Haemophilia Treatment and Comprehensive Care Centres (HTC/CCCs).Methods: The co‐creation process, supported by the European Association for Haemophilia and Allied Disorders, consisted of four multidisciplinary meetings with health care providers (HCPs) experienced in WGBD care, and European Haemophilia Consortium representatives, combined with broad patient and HCP consultations in the European haemophilia community. Relevant medical societies outside Europe were contacted for confirmation.Results: We developed ten PoC for WGBD, stressing the importance and benefits of a centralized, multidisciplinary, comprehensive, family‐centred approach to support and manage WGBD during all life stages. These PoC emphasise the right to equitable access and quality of care for all people with BDs, irrespective of gender. Multiple medical societies outside Europe also confirmed their support for endorsement.Conclusions: Ten PoC for WGBD evolved from an iterative process among stakeholders, supported by relevant medical societies worldwide. These PoC can serve as a benchmark for diagnosis and comprehensive multidisciplinary management of WGBD, and improve awareness of their unique challenges. They offer a framework to guide HTC/CCCs in providing equitable care for all WGBD, both in their own services and in other healthcare settings. Implementation of these principles aims to positively impact the health, wellbeing and quality of life for WGBD.